CRISPR Therapeutics: Analysts’ View in November

On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.

CRISPR Therapeutics’ stock price opened at $24.00 on January 2 and reached $36.37 on November 9, which represents ~52% year-to-date growth. CRISPR Therapeutics hit its 52-week high of $73.90 on May 24. Notably, CRISPR Therapeutics had its 52-week low of $16.51 on November 9, 2017.

After the third quarter on September 30, CRISPR Therapeutics had net cash and cash equivalents of $487.3 million—compared to $319.7 million at the end of the second quarter on June 30. CRISPR Therapeutics’ net cash and cash equivalents grew 167.6 million during the third quarter. The September follow-on offering mainly contributed to the company’s increased cash.

Of 11 analysts tracking CRISPR Therapeutics in November, one analyst recommended a “strong buy,” six analysts recommended a “buy,” three analysts recommended a “hold,” and one analyst recommended a “sell” rating.

On November 12, CRISPR Therapeutics had a consensus 12-month target price of $66.39, which represents an ~83.37% return on investment over the next 12 months.

In November, of the 11 analysts tracking Editas Medicine (EDIT), ~55% of them recommended a “buy.” Among the nine analysts tracking Intellia Therapeutics (NTLA), ~56% of them recommended a “buy.” Of the eight analysts tracking Sangamo Therapeutics (SGMO), ~75% of them recommended a “buy.”

On November 12, Editas Medicine, Intellia Therapeutics, and Sangamo Therapeutics had consensus 12-month target prices of $44.93, $43.25, and $26.43, respectively, which represents an ~55.20%, ~130.30%, and ~136.93% return on investment over the next 12 months.